In recent years, there has been an increase in the incidence of foot mycosis and onychomycosis, which affect up to 20 % of the world’s population and have significant social significance. Onychomycosis most often occurs in older people and is a common reason for visiting a dermatologist. Despite improvements in the treatment of patients with onychomycosis, the problem of effective and safe treatment remains relevant due to the drug burden on hepatocytes when prescribing systemic antimycotics. This necessitates the need to improve approaches to the treatment of patients with onychomycosis and reduce the risk of side effects when using systemic antimycotics. Systemic antimycotics (Тerbinafine) are metabolized in the liver through the cytochrome P450 system, which can cause drug load, especially in elderly patients. Objective — to assess the dynamics of enzymatic and pigmentary activity of the hepatobiliary system in patients receiving long-term therapy with Тerbinafine, and to determine the protective potential of silymarin in preventing metabolic disorders of the liver. Materials and methods. The total number of participants was 100 (70 patients + 30 healthy individuals for control). Patients were randomly divided into groups: the main group, which received a Terbinafine and silymarin, and the comparative group, which received only the Terbinafine. Control group: 30 healthy individuals (to establish physiological norms). The diagnosis was confirmed clinically and mycologically (culture on Sabouraud medium). Biochemical parameters (ALT, AST, bilirubin, alkaline phosphatase) were determined using standard methods. Statistical processing was performed in EXCEL-2003® and STATISTICA 6.1. Results and discussion. In most patients with onychomycosis, T. rubrum 60 (85.7 %) was detected, less frequently — T. mentagrophytes var. interdigitale and Scopulariopsis brevicaulis. Most patients (62.0 %) with onychomycosis who were under our observation were over 51 years of age. An analysis of the trends in biochemical parameters revealed differences between the study groups at the end of the treatment course: in the control group, there was a tendency toward increased levels of total bilirubin and aminotransferases (ALT and AST). In the main group, liver function test results remained stable throughout the entire observation period. Despite fluctuations in the first group, no patient developed drug-induced hepatitis or required premature discontinuation of treatment due to hepatotoxicity.The use of silymarin increases the safety of Terbinafine and reduces its effect on liver cells. Conclusions. The use of silymarin systemic therapy with Terbinafine is an important strategy for reducing the risk of adverse drug effects on the liver. Since systemic antifungals are known for their hepatotoxicity — as they are metabolized via the cytochrome P450 system in the liver, placing a certain burden on hepatocytes and elevating liver enzyme levels. The inclusion of silymarin in the comprehensive treatment of patients with onychomycosis during systemic use of Terbinafine allowed for the stabilization of serum transaminase activity and alkaline phosphatase levels, which is appropriate and clinically justified, as it allows the patient to complete a full course of antifungal therapy without complications for the liver.